Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire Plc. SHPG announced that its Japanese partner Shionogi & Co., Ltd submitted a new drug application (NDA) for the manufacture and marketing of Intuniv (guanfacine hydrochloride extended release) in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.